Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Well I can assure you personally that data is wrong
Absolutely not true. Buys are showing up red/sells.
The crux to me here is the major shareholder and shareholders are not selling as far as we know, leading up to phase 3 trial results , Lombard off loaded many millions of shares only to buy back in when they tanked on results. We the share holders are the impatient ones, only literally a couple of weeks into March, yet the company have expressed release in first six months. FDA approval imminent, positive result will lead to the start of the fireworks.
The company got it completely wrong first time round with CSD, now holding all the cards JB said at the AGM that he expected to provide shareholders with good news throughout the coming year. Nearly there, have belief, the company will not mess this up.
Are you sure, share price now lagging 30/32p behind Greencoat having been virtually at parity 18 months / 2 years ago, plus a 5% rise in the dividend against UKW 13% rise.
I’d suggest the board need to have a hard look at themselves along with the companies advising them. The share price other than a few spikes and lows has remained at this level for far far too long.
I was responsible for a £10.5k buy yesterday, it appeared as a sell.
Take everything with a pinch of salt leading up to FDA approval, so much rubbish on the internet, on this occasion Paperdrunk sums it up pretty well.
Personally I’ll wait until either Coopers, who have not yet even announced it on their site or FUM come out and inform us. I will also be astonished if Eroxon has not been launched in time for Feb 14th, only three weeks away, it would simply have to be the number one buy for the time of year with all the publicity it would surround the first proven product for ED since Viagra.
I go back to a subject I posted on previously, the institutions are undoubtably in command of this company and ultimately Eroxon and not one sell from what we know to date. They now have significant monies invested here, that says a lot.
Static over the last six months will do me just fine, especially when you see some carnage out there. I suspect many investors would love to have trodden water along with the expectations we await in the New Year!
Plus I doubt there are many stocks with the potential of FUM running into 2023, but it’s about time!
No misapplication side effects, simply as I understand, the gel in a phase 2 trial was applied incorrectly (too the wrong area of the *****), this lead to FUM conducting a phase 3 trial at enormous expense. It was doomed from the outset, consequently though Med 3000 was born. Contains no drugs and if reciprocates in real life as it has done in two trials and test run by European partner, I expect this to absolutely fly.
Obviously crucial then that the gel is applied to the glands ***** under the correct environment , otherwise I believe it will not have the desired effect. Seems to me that the instructions are paramount for Med 3000 success.
All very quiet, eight weeks until Christmas so highly unlikely any launch prior, as JB suggested.
So when and where? Could FUM be planning along with their partners for one sensational launch leading up to Valentines Day? Can you imagine magazines and day time TV in overdrive, a new proven over the counter gel with a European kite mark for ED, completely safe for all users. If they do , I believe it will be one fantastic coop along with I suspect plenty of free advertising.
FUM as we know have had plenty of time to put everything in place, perhaps this has been their long term plan. I could honestly see this being a case of out of stock around the various outlets if I’m correct, as demand May outstrip supply.
The key to the success of Eroxon now is I believe something small but absolutely crucial, INSTRUCTIONS ON USE. We know to our expense the implications of when the gel is applied to the wrong area of the *****, along with exactly when to use it is what I’m most keen to see when it becomes available.
If the renewables end up receiving less money for the power they produce, it will inevitably lead to an issue of companies finding it not worth while investing in new infrastructure, which as we speak will be rising rapidly in cost to build.
This country and even continent are becoming a laughing stock.
https://au.finance.yahoo.com/news/futura-medical-plc-lon-fum-143710133.html
Institutions have control, stand to make a fortune if Eroxon is successful, still appear not to be selling any stock. Does that tell us something?
Do hope that I’m not tempting fate, but there is one subject that stands out for me over this year. Not one the largest shareholders including Lombard have reduced their holding, leading up to the phase 3 trial result back in Dec 2020, Lombard off loaded a considerable amount. In fact Lombard increased by around 2% back in April/May of this year.
I cannot imagine that a company like Lombard are going to sit around if there wasn’t true belief. Without looking I think they hold around 25-27% of FUM. I’m sure like everyone there will be a time to take some profits. But considering the fairly large sells over the last few months I believe this bodes well in the belief and future of Eroxon.
Hopefully with FDA approval being expected in 5/6 months time, FUM with knowledge gained from there work closer to home, will in the meantime put everything in place so that launch in the US can happen shortly after receiving confirmation.
We certainly do not want or expect to be waiting for very long for the biggest market in the world to come online. Today I would say that FUM is in the strongest position it ever has been, with all the ground work having been put in place over this last 18 months, there can be no further excuses. Some shareholders have been waiting for this moment for far too many years, but we are arriving at the station and I hope FUM management and staff are going to deliver and make this company and product into a successful and known brand worldwide.
81Lucky, your last line ,” hostile takeover over”, whether or not hostile , I believe you are right! This is looking primed to be taken over in my eyes. My personal thoughts are sales are going to be massive, why would anyone not give it a go with everything we know about Eroxon against the other alternatives. Also I don’t care what the market thinks of the BoD’s. They have a plan and are quietly implementing it, making sure they can deliver their end and personally I think the company will eventually be taken over. If FUM get it right their end and deliver, it should be at an exceptionally cracking price.